Company Profile
Immunovant Stock Price, News & Analysis
- Ticker:
- IMVT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
39.37 USD (+0.82%)
Close
Last updated: July 23, 2026
6.35B USD
Market cap
Why the stock is moving
IMVT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Immunovant is an immunology company focused on FcRn inhibition for autoantibody-driven diseases.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Immunovant sits in clinical-stage autoimmune biotechnology.
Business Model Characteristics
Its model is built around proof-of-concept data, dose optimization, and the potential to expand into multiple antibody-mediated diseases.
Position Within the Biotechnology Landscape
Immunovant is a catalyst-heavy immunology name whose stock reacts to clinical differentiation and platform confidence.
Future catalysts
Immunovant is heading into a more important stretch around IMVT-1402. Management's latest framing highlights Recent Highlights and Upcoming Milestones: The Company announced preliminary Week 16 (end of Period 1) results from the IMVT-1402 trial in D2T RA with ACR20, ACR50, and ACR70.... The stock is likely to react most to whether those milestones keep moving without a reset.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
BRKR · Source: Bruker
- 02
- 03
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
DGX · Source: Quest Diagnostics
- 04
Molina Healthcare Reports Second Quarter 2026 Financial Results
MOH · Source: Molina Healthcare
- 05
Axon to Release Second Quarter 2026 Earnings on August 5, 2026
AXON · Source: Axon Enterprise, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immunovant (IMVT)?
Immunovant (IMVT) most recently closed at 39.37 USD, a +0.82% move versus the previous session.
What is the market cap of Immunovant (IMVT)?
Immunovant currently has a market capitalization of 6.35B USD on BioPharmSignal.
What does Immunovant do?
Immunovant is an immunology company focused on FcRn inhibition for autoantibody-driven diseases.
On which exchange is IMVT stock listed?
Immunovant (IMVT) is associated with NASDAQ, United States, Biopharma.
What is IMVT-1402?
Immunovant is heading into a more important stretch around IMVT-1402.
Which conditions is Immunovant targeting with IMVT-1402?
Immunovant is associated with immunology based on its company overview and current catalyst commentary.
How does Immunovant describe recent progress with IMVT-1402?
Immunovant is heading into a more important stretch around IMVT-1402.
What is Immunovant?
Immunovant is an immunology company focused on FcRn inhibition for autoantibody-driven diseases.